GPT and metabolic dysfunction-associated steatotic liver disease: As shown in Figure 6(B) and (C), curcumin encapsulated by Targeted tFNAs (Group V) was found to significantly curtail the plasma ALT (Group II: 31.03 ± 11.36 U/L; Group V: 18.22 ± 4.372 U/L; p = 0.0275) and AST (Group II: 65.77 ± 19.32 U/L; Group V: 43.32 ± 4.437 U/L; p = 0.0196) activities in NAFLD mice.